Personnel Moves Archives - Page 26 of 42

Johnson & Johnson MedTech appoints new CFO

Johnson & Johnson MedTech (NYSE:JNJ) announced that Kurt Van den Bosch has been appointed as its CFO, group finance.

Van den Bosch will be a member of Johnson & Johnson’s global finance team, reporting to the company’s EVP and CFO Joe Wolk. Van den Bosch’s role includes providing financial leadership to the global Johnson & Johnson MedTech organization.

He most recently served as area VP of mid-sized markets for J&J MedTech EMEA, overseeing the EMEA business that included the markets of Austria, Belgium, Greece, Israel, Portugal, Switzerland, the Netherlands and Scandinavian countries.

Van den Bosch joined Johnson & Johnson’s Janssen Pharmaceuticals, Belgium, company in 1990 as part of its finance team and has held a range of roles with increasing responsibility since. Before joining J&J MedTech, he was CFO for Janssen EMEA from 2012 to 2014, before being appointed to the role of CFO for global surgery EMEA…

Shacey Petrovic to step down as Insulet CEO, ResMed exec Jim Hollingshead to take role

Insulet (Nasdaq:PODD) announced today that President and CEO Shacey Petrovic will step down for personal family reasons.

Petrovic will step down from her position effective June 1, 2022, but will continue to serve on the company’s board. She will also serve as an advisor to the company through May 2023 to support the leadership transition to Jim Hollingshead, who will succeed Petrovic effective June 1.

Hollingshead has served as an independent member of Insulet’s board of directors since 2019 and currently serves as president of sleep and respiratory care at ResMed.

Get the full story at our sister site, Drug Delivery Business News.

iRhythm brings Stanford professor into C-suite

iRhythm Technologies (Nasdaq:IRTC) this week announced it appointed Mintu Turakhia as chief medical officer and chief scientific officer.

Turakhia is a professor of medicine at the Stanford University School of Medicine and the director and cofounder of the Stanford Center for Digital Health. He is also a cardiac electrophysiologist with more than 20 years of experience in patient care, outcomes research and trials, data science and artificial intelligence, medical device regulation and the create and commercialization of digital health products.

According to the company, Turakhia performed the first study of silent atrial fibrillation with iRhythm’s original Zio patch, which helped the company perform large atrial fibrillation studies at scale.

“As healthcare continues to evolve at a rapid pace, we are very excited to add Dr. Turakhia to our executive team,” CEO Quentin Blackford said in a news release. “Mintu is a prolific scientist, respected cl…

Iradimed slides despite strong Q1, chief financial, operating officer resigns

Iradimed (Nasdaq:IRMD) shares took a hit this morning despite Street-beating first-quarter results and increased financial guidance.

IRMD shares were down 12.2% at $36.17 per share in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down 0.1%.

The Winter Springs, Florida-based company posted profits of $2.5 million, or 20¢ per share, on sales of $12.3 million for the three months ended March 31, 2022, for a 79.3% bottom-line gain on sales growth of 33.5%.

Adjusted to exclude one-time items, earnings per share were 22¢, 2¢ ahead of Wall Street, where analysts were looking for sales of $12.2 million.

“I am very satisfied with these results. Having the first quarter start off strongly shows the continued strength of our business. Our growth afforded us the opportunity to pay a special dividend of $1.00 per share during the first quarter,” Iradim…

Glooko adds former Eli Lilly exec to its board of directors

Diabetes management technology developer Glooko announced today that it appointed Alfonso “Chito” Zulueta to its board of directors.

Zulueta joins Palo Alto, California-based Glooko’s board having spent more than 30 years with Eli Lilly and Company, serving as a senior executive across an array of global business and commercial units.

Get the full story at our sister site, Drug Delivery Business News.

Sweetch adds American Diabetes Association exec to its advisory board

Chronic condition therapeutic developer Sweetch announced today that Dr. Robert A. Gabbay has joined the company as an advisor.

Gabbay currently serves as the chief scientific and medical officer at the American Diabetes Association, leading the organization’s efforts to drive discovery in diabetes research, care and prevention. He also serves as an associate professor of medicine at Harvard Medical School, having previously been CMO at Joslin Diabetes Center.

Get the full story at our sister site, Drug Delivery Business News.

Medtronic names Dr. Laura Mauri as chief scientific, medical, regulatory officer

Medtronic (NYSE:MDT) this week announced it appointed Dr. Laura Mauri as chief scientific, medical and regulatory officer.

Mauri most recently was the chief clinical and regulatory officer for Medtronic. She joined the company in September 2018 and was appointed to the Dublin-based company’s executive committee in August 2020. Mauri succeeds Richard Kuntz whose previously announced retirement takes effect on April 29.

Prior to joining the company, Mauri was a practicing interventional cardiologist at Brigham and Women’s Hospital for 15 years and was an investigator and professor of medicine at Harvard Medical School.

“With this appointment, we’re enabling a patient-centered approach to healthcare technology innovation at every stage of the product lifecycle,” CEO Geoff Martha said in a news release. “Dr. Mauri’s expertise and leadership connects medical and scientific intelligence, ensuring we have a clear apprai…

Globus Medical stock down after surprise CEO transition

Globus Medical (NYSE: GMED) stock is down more than 11% today, a day after the musculoskeletal repair tech company announced the surprise resignation of its CEO.

Dave Demski said in a news release that he was stepping down as CEO to pursue other opportunities, with the board promoting Chief Commercial Officer Daniel Scavilla into the corner office.

GMED shares were down more than 11% at $69.85 apiece in morning trading today.

The surprise CEO transition came at the same time that the company announced that it expects to report roughly $230.5 million for the quarter ended March 31, 2022, up 1.4% from Q1 2021. The Street had expected nearly $236 million in revenue. (Globus Medical plans to announce first-quarter results after the market closes on May 10.)

BTIG analysts related that Demski in a conference call after the resignation announcement said he had nothing specific lined up, just that it was time to step aside and seek a new challenge.

ReWalk Robotics appoints Fresenius, Boston Scientific veteran to its board

ReWalk Robotics (Nasdaq:RWLK) announced that it appointed Joseph Turk, Jr. to its board of directors.

The appointment was made effective on April 20.

Turk joins the Marlborough, Massachusetts-based robotic medical technology developer having begun his career at McKinsey and Company before joining Boston Scientific as its director of new business development.

He also held leadership roles — including that of president — at NxStage Medical. He currently serves as EVP and president of the renal therapies group at Fresenius Medical Care North America.

“Being able to improve people’s lives through commercializing novel technologies has been a driving force in my career,” Turk said in a news release. “Working with a mission-driven company with life-changing technologies such as ReWalk is a natural fit. I look forward to contributing my insight to help ReWalk develop successful broad commercialization strategies that enable better health for the disabled…

Butterfly Network names new CFO

The Butterfly Network IQ+ system [Image courtesy of Butterfly Network]Butterfly Network (NYSE:BFLY) announced today that it appointed Heather Getz as its new EVP and chief financial officer (CFO).

Getz’s appointment to the positions of EVP and CFO of the Guilford, Connecticut-based developer of handheld ultrasound technology will be made effective May 2.

“Heather brings a compelling blend of healthcare technology and public company experience along with a successful track record in operational and financial discipline that is well suited to support and enhance Butterfly’s continued growth and evolution,” Butterfly President and CEO Dr. Todd Fruchterman said in a news release. “As a proven CFO with deep experience in delivering results and value creation, Heather will be a strong partner as we continue to execute our strategy and introduce unique value to the healthcare ecosystem.”

Getz most recently spent 12 years at BioTelemetry where, among o…

Dentsply Sirona sacks its CEO

Dentsply Sirona (Nasdaq: XRAY) announced today that it has fired CEO Don Casey, who has held the corner office at the dental products and technologies company since 2018.

XRAY shares were down more than 13% to $42.20 apiece by today’s close of trading.

Board member John Groetelaars, who was CEO of Hillrom until its acquisition by Baxter late last year, will serve as interim CEO.

Barbara Bodem, the CFO at Hillrom under Groetelaars, is joining Dentsply Sirona as interim CFO effective April 25. Outgoing CFO Jorge Gomez was already in the process of leaving to assume a similar role at Moderna.

Charlotte, North Carolina-based Dentsply Sirona didn’t directly explain the CEO change, but the numbers likely tell the story.

In the same news release announcing the termination of Casey’s employment, Dentsply Sirona released anticipated Q1 financial results of adjusted EPS in the range of 48–52¢, with sales expected to decline 1.4% yea…

Wytech Industries announces new CEO

Wytech Industries CEO David Ohmann [Image from Ohmann’s LinkedIn page]

Wytech Industries, a Vance Street Capital portfolio company, announced today that it has promoted David Ohmann to the corner office.

Ohmann joined Wytech in May 2021 as president. A veteran of Heraeus and TE Connectivity’s MicroGroup, he has more than 25 years of medical device industry experience.

“Over the past eleven months Dave’s energy, dedication and compassion for the people of Wytech has preserved the entrepreneurial and employee-focused culture that the Casalino family started 50 years ago,” said Mike Janish, managing partner of Vance Street Capital.

“Wytech’s three-year growth plan now includes an expansion of manufacturing space at the Rahway [New Jersey] facility, including continuous expansion of Wytech’s FastLane Webstore. We are very happy with Wytech’s scalability and excited for Dave’s p…